Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiocell
- Development stage
- Unknown
- Lead developer
- Brady Pharma
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Sublingual, Buccal
01
Overview
Thiocell is an oral dietary supplement formulated as a chewable lozenge for skin whitening, anti-aging, and immune support. Developed by Dr. Theodore Hersh of Thione International and commercialized by Brady Pharma, the product features a synergistic combination of L-glutathione, vitamin C, and L-selenomethionine (known as the GCS synergy), along with vitamin D, vitamin E, and grape seed extract. The lozenge formulation is designed to facilitate absorption of glutathione through the oral cavity (buccal/sublingual mucosa) rather than the stomach, bypassing first-pass metabolism to maximize bioavailability and efficacy in reducing melanin production and pigmentation.
- Brand names
- Thiocell
- Other names
- Thiocell GlutathioneThiocell Glutathione Lozenges
02
Targets
TYR (Tyrosinase)
Beyond the preview
Go deeper on Thiocell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thiocell.